Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)-Reference-Cited by-同舟云学术

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)

Published:2014-03 Issue:3 Volume:15 Page:267-274
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

André Fabrice,Bachelot Thomas,Commo Frederic,Campone Mario,Arnedos Monica,Dieras Véronique,Lacroix-Triki Magali,Lacroix Ludovic,Cohen Pascale,Gentien David,Adélaide Jose,Dalenc Florence,Goncalves Anthony,Levy Christelle,Ferrero Jean-Marc,Bonneterre Jacques,Lefeuvre Claudia,Jimenez Marta,Filleron Thomas,Bonnefoi Hervé

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Breast cancer statistics;Desantis;CA Cancer J Clin,2013

2. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study;Cortes;Lancet,2011

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

4. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups;Curtis;Nature,2012

5. The landscape of cancer genes and mutational processes in breast cancer;Stephens;Nature,2012

Cited by 346 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational study;The Oncologist;2024-08-23

2. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study;BMJ;2024-08-20

3. Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy;BMC Cancer;2024-07-28

4. Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology;Clinical and Translational Oncology;2024-06-13

5. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies;JAMA Oncology;2024-05-01